Passage Bio (NASDAQ: PASG)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-03 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.830 | -0.730 | 0.1000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Passage Bio (NASDAQ: PASG) through any online brokerage.
Other companies in Passage Bio’s space includes: Fortress Biotech (NASDAQ:FBIO), Anixa Biosciences (NASDAQ:ANIX), CytomX Therapeutics (NASDAQ:CTMX), OncoCyte (NASDAQ:OCX) and TCR2 Therapeutics (NASDAQ:TCRR).
The latest price target for Passage Bio (NASDAQ: PASG) was reported by Citigroup on Tuesday, May 17, 2022. The analyst firm set a price target for 10.00 expecting PASG to rise to within 12 months (a possible 350.45% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Passage Bio (NASDAQ: PASG) is $2.22 last updated August 5, 2022, 8:00 PM UTC.
There are no upcoming dividends for Passage Bio.
Passage Bio’s Q3 earnings are confirmed for Thursday, November 3, 2022.
There is no upcoming split for Passage Bio.
Passage Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.